Ubiquitous neurocognitive dysfunction in familial adenomatous polyposis: proof-of-concept of the role of APC protein in neurocognitive function by Cruz-Correa, Marcia Roxana et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2020-02-24 
Ubiquitous neurocognitive dysfunction in familial adenomatous 
polyposis: proof-of-concept of the role of APC protein in 
neurocognitive function 
Marcia Roxana Cruz-Correa 
University of Puerto Rico 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cancer Biology Commons, Cognitive Neuroscience Commons, Congenital, Hereditary, and 
Neonatal Diseases and Abnormalities Commons, Neoplasms Commons, Nervous System Commons, 
Nervous System Diseases Commons, and the Neurology Commons 
Repository Citation 
Cruz-Correa MR, Sala AC, Cintron B, Hernandez J, Olivera M, Cora A, Moore CM, Luciano CA, Soto-Salgado 
M, Giardiello FM, Hooper SR. (2020). Ubiquitous neurocognitive dysfunction in familial adenomatous 
polyposis: proof-of-concept of the role of APC protein in neurocognitive function. Open Access Articles. 
https://doi.org/10.1186/s13053-020-0135-3. Retrieved from https://escholarship.umassmed.edu/
oapubs/4307 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
RESEARCH Open Access
Ubiquitous neurocognitive dysfunction in
familial adenomatous polyposis: proof-of-
concept of the role of APC protein in
neurocognitive function
Marcia Roxana Cruz-Correa1,2,4,5* , Ana Cecilia Sala1, Beatriz Cintrón1, Jessica Hernández1, Myrta Olivera1,
Adrian Cora1, Constance M. Moore6, Carlos A. Luciano3, Marievelisse Soto-Salgado1, Francis M. Giardiello5 and
Stephen R. Hooper7
Abstract
Background: Familial adenomatous polyposis (FAP) is an autosomal dominant disorder caused by germline
mutations in the APC gene. Patients with FAP have multiple extraintestinal manifestations that follow a genotype-
phenotype pattern; however, few data exist characterizing their cognitive abilities. Given the role of the APC protein
in development of the central nervous system, we hypothesized that patients with FAP would show differences in
cognitive functioning compared to controls.
Methods: Matched case-control study designed to evaluate cognitive function using the Test of Nonverbal
Intelligence-4, the Bateria III Woodcock-Munoz, and the Behavior Rating Inventory of Executive Functions-Adult.
Twenty-six individuals with FAP (mean age = 34.2 ± 15.0 years) and 25 age-gender and educational level matched
controls (mean age = 32.7 ± 13.8 years) were evaluated.
Results: FAP-cases had significantly lower IQ (p = 0.005). Across all tasks of the Batería III Woodcock-Muñoz, FAP-
cases performed significantly lower than controls, with all of the summary scores falling in the bottom quartile
compared to controls (p < 0.0001). Patients with FAP scored within the deficient range for Long-Term Retrieval and
Cognitive Fluency.
Conclusion: APC protein has an important role in neurocognitive function. The pervasive nature of the observed
cognitive dysfunction suggests that loss or dysfunction of the APC protein impacts processes in cortical and
subcortical brain regions. Additional studies examining larger ethnically diverse cohorts with FAP are warranted.
Keywords: Familial adenomatous polyposis, Neurocognition, Hispanics, FAP
Introduction
Familial adenomatous polyposis (FAP) is an autosomal
dominant disorder caused by germline mutations in the
Adenomatous Polyposis Coli (APC). There are multiple
extraintestinal manifestations that follow a genotype-
phenotype pattern [1]; however, few data characterize the
cognitive abilities of individuals with FAP. The APC pro-
tein has a major function in the development of the cen-
tral nervous system, including a pivotal role in the
development of the pre-post synaptic complex seen in in-
vivo [2] and animal studies [3]. Moreover, high concentra-
tions of the APC protein are present in the hippocampus,
thalamus, and limbic system. Consequently, specific diffi-
culties in the neurocognitive domains of attention, mem-
ory, and executive functions among individuals with
deficient APC protein function might be expected.
Despite these known linkages few empirical findings
examining the relationship between the expression of
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the APC protein and neurocognitive and behavioral
functioning in individuals with APC mutations exist [4–
7]. To date, animal studies have associated APC dysfunc-
tion with altered synaptic function in APC cKO mice,
which plays a critical role in learning and memory [8].
The genetic changes in APC that have been implicated
in learning and memory deficits, repetitive behaviors,
and reduced social interest [8], also have been associated
with working memory deficits, increased locomotion,
and anxiety-related behavior [3]. Though frequently hy-
pothesized that genetic factors play an important role in
psychiatric disorders, identification of specific genes has
been a difficult task. Interestingly, preliminary findings
implicate the APC gene in psychiatric disorders such as
schizophrenia [9, 10] and depression [11]. These psychi-
atric conditions have also been related to cognitive and
behavioral impairments.
The primary aims of this exploratory study were to de-
termine: (1) whether patients with FAP would evidence
differences in performance on measures of neurocogni-
tive function compared with non-affected controls; and
(2) if neurocognitive manifestations followed a genotype-
phenotype distribution as seen with other clinical mani-
festations in FAP. Given the major role of the APC pro-
tein in the development of the central nervous system,
including the development of the pre-post synaptic com-
plex seen in in vitro [2, 12] and in vivo [8] studies, we
hypothesized that individuals with FAP would show
lower cognitive functioning compared to non-FAP con-
trols across all ages. Given the potential for synaptic dys-
function, we would expect tasks related to processing
speed and cognitive efficiency to be the most affected.
Methods
Participants
Sample size calculations were based on data from
O’Malley et al. [13] who reported a lower Verbal IQ for
individuals with FAP compared to historical average
scores. Using the Batería III Woodcock-Muñoz, with a
mean IQ = 100 (SD = 15) a sample size of 23 in each
group will have 90% power to detect a probability of
0.240 (effect size) that an observation in Group 1 is less
than an observation in Group 2 using a Wilcoxon
(Mann-Whitney) rank-sum test with a 0.050 two-sided
significance level. Participants for both groups (ages ≥10
years) were ascertained via the Puerto Rico Familial
Colorectal Cancer Registry (http://purificar.rcm.upr.edu/
index_eng.html).
Inclusion criteria for cases included genetically con-
firmed FAP (based on a mutation on the APC gene per-
formed by commercial laboratory testing), age ≥ 10 years,
able to assent (children) and consent (adults) to partici-
pate in this study, and able to complete all neurocogni-
tive testing. Inclusion criteria for controls included no
known family history of FAP, negative clinical diagnosis
of FAP based on colonoscopy (for adults), and willing-
ness to undergo neurocognitive testing. Participants
were all Spanish-speaking individuals from Puerto Rico.
As education and age are correlated with IQ, cases were
matched to non-FAP control individuals with regards to
age (± three years), gender, and education (less than high
school, at least high school, bachelors-degree or post-
graduate education). Exclusion criteria for both cases
and controls included previous diagnosis of any
major psychiatric condition given the potential impact of
these conditions on neurocognitive functioning, inability
to sign/assent/consent study participation, or complete
the neurocognitive tests.
Participants signed informed consent (or assent for
children) prior to participation in the study and were
evaluated at the Puerto Rico Clinical and Translational
Research Consortium at the University of Puerto Rico
(UPR) Medical Sciences Campus. The research protocol
was approved by the Institutional Review Board of the
UPR Medical Sciences Campus.
Measures and procedures
Neurocognitive procedures were carried out by licensed psy-
chologists with extensive expertise in evaluation of neuro-
cognitive disorders in children with genetic conditions.
Selection of measures for this study was based on the fol-
lowing criteria: (1) tests have hypothesized links to brain re-
gions where there are known high concentrations of APC
protein; (2) age-appropriateness, with tasks going across the
lifespan; (3) well established standardization and age-based
normative data; and (4) strong psychometric properties.
These outcome measures included the Test of Nonverbal
Intelligence-4, the Batería III Woodcock-Mũnoz, and the
Behavior Rating Inventory of Executive Functions-Adult.
Measures of anxiety (General Anxiety Disorder
Questionnaire-7), social communication (Social Communi-
cation Questionnaire), and depression (Patient Health
Questionnaire-9) were used as potential covariates.
Batería III Woodcock-Mũnoz We used the cognitive
components of this battery, which was translated and
adapted from the publisher of the Woodcock-Johnson III
Cognitive Battery via a calibration sample of approximately
1400 individuals from both the United States and several
Spanish speaking countries including Puerto Rico. This bat-
tery is based on the Cattell-Horn-Carroll model of cognitive
abilities and includes measures of comprehension-
knowledge, visual-spatial thinking, auditory processing, pro-
cessing speed, short-term memory, long-term memory,
working memory, broad attention, and executive processes.
This measure retains a high degree of technical adequacy
with reliability for all of the clusters being ≥0.90 across all
of the age ranges.
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Test of nonverbal intelligence (TONI-4) Although the
Batería III Woodcock-Mũnoz can generate a General In-
tellectual Factor, its use as a covariate in any of our ana-
lyses will confound group findings from the cognitive
clusters as the intellectual estimate contains many of the
same subtests. In that regard, for our overall measure of
intellectual functioning, we have included a nonverbal
measure of intellectual functioning: the TONI-4. While
hoping to utilize the KBIT-2 to replicate the findings of
O’Malley et al. [13] there is no Spanish version of this
test; consequently, using the TONI-4 provides a broader
application for our sample and serves as a subject de-
scriptive variable and as a potential covariate in the data
analyses. The TONI-4 measures the ability to solve
problems without overtly using language or complex
motor responses, requiring the person to apply reason-
ing strategies to a problem defined by novel abstract fig-
ures. It includes verbal directions in Spanish, and
responses require only simple pointing or gestures. The
psychometric properties and normative basis of the
TONI-4 are strong.
Behavior rating inventory of executive functions
(BRIEF)-parent and adult versions The BRIEF is a be-
havior rating scale of executive functions in everyday life
that is completed by the parent (up to age 18 years) or an
individual (ages 18 and older). The BRIEF provides eco-
logical measures of a variety of executive functions that
address regulatory activities in day-to-day functioning. It
comprises specific clinical scales (e.g., Organization, Shift,
Working Memory, etc.) and three summary scales: Behav-
ioral Regulation Index, Metacognition Index, and Global
Executive Composite. Each version of the scale is stan-
dardized, well normed, has strong psychometric proper-
ties, and is available in both English and Spanish.
Patient health questionnaire (PHQ9) The PHQ9 is a
nine-item depression scale completed by the individual.
It is a multiple-choice self-report inventory used as a
screening and diagnostic tool for depression, anxiety, al-
cohol, eating, and somatoform conditions.
Generalized anxiety disorder (GAD-7) The GAD-7 is
a self-reported questionnaire for screening and severity
of generalized anxiety disorder. The GAD-7 has seven
items, which measure severity of various signs of gener-
alized anxiety disorder according to reported response
categories with assigned points.
Neurological exam
All patients underwent a full neurologic examination
exam performed by a neurologist that included a screen-
ing for mental status, apraxia, agnosia, aphasia, cranial
nerve status, motor and sensory intactness, motor coord-
ination, and deep tendon and corticospinal tract reflexes.
Data analyses
Preliminary data analyses included a comparison of se-
lected sociodemographic characteristics by study group
(FAP vs. Control) using χ2 test or Fisher’s exact test. The
anxiety and depression scores were compared by study
group (FAP vs. Control) using t-tests or Wilcoxon rank-
sum test. To address group differences in neurocogni-
tion, simple and multiple linear regression models were
used to estimate the unadjusted and adjusted beta (B)
coefficients with their 95% confidence intervals. The
models were adjusted by age, gender, and educational
level. P-values were corrected using the Bonferroni-
Holm method (https://www.statisticshowto.datascience-
central.com/holm-bonferroni-method/). To establish sig-
nificance, observed p-values were compared with
corrected p-values. If (1) observed p-values were lower
than corrected p-values, and (2) there was an intersec-
tion between the significant p-values across the tests for
each measure, then, neurocognitive measure was estab-
lished to be significant.
For the evaluation of neurocognitive function status
across the APC gene mutation spectrum, FAP patients
were stratified according to location of mutations in the
gene. Specifically, genotype-phenotype analysis was per-
formed comparing individuals with mutations in codons
within the attenuated-FAP region (codons < 1000 and >
1500; N = 9) and those within the mutation cluster region
(between codons 1000 to 1500; N = 17). To determine the
effect of the FAP genotype-phenotype, we used simple lin-
ear regression models and adjusted linear regression
models with 95% confidence intervals. The models were
adjusted by age, gender, and educational attainment. Stat-
istical analyses were performed using Stata 14.0.
Results
Baseline demographic and clinical characteristics
Baseline demographic characteristics are presented in
Table 1. Study participants (cases and controls) were
equivalent with regards to age (mean age 34.2 ± 15.0 vs.
32.7 ± 13.8, p = 0.59), gender (p = 0.68), and educational
level (p = 0.10), with both groups being unremarkable in
the reporting of their symptoms. There were no statisti-
cally significant differences between patients with FAP
and controls with regard to baseline anxiety (p = 0.21)
and depression (p = 0.09) (data not shown).
Intelligence
Group differences on the TONI-4, our measure of
Intelligence, are presented in Table 2. Both FAP cases
and controls fell within the average range of functioning,
although the FAP patients had statistically significantly
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lower functioning compared with age-, gender- and
education-matched controls (90.5 ± 5.6 vs. 95.6 ± 6.8,
p = 0.008).
Neurocognitive functioning
Batería-III summary scores Findings of the groups on
the Batería-III summary scores are shown in Table 2.
Across all of the Batería-III summary scores, FAP cases
reflected significantly more risk for cognitive dysfunction
than the controls, with the cases showing performances
in the lower quartile on Verbal Ability, Thinking Ability,
Cognitive Efficiency, Long-Term Retrieval, Processing
Speed, Phonemic Awareness, Working Memory, Cogni-
tive Fluency, and Executive Processes. In particular, FAP
cases scored within the deficient range for Long-Term
Retrieval and Cognitive Fluency.
Specific group comparisons on the obtained scores re-
vealed a similar pattern of findings wherein the FAP Group
performed significantly lower than controls on: Verbal Abil-
ity (LRM − 7.2, p = 0.002); Thinking Ability (LRM − 16.9,
p < 0.0001; Cognitive Efficiency (LRM − 13.3, p < 0.0001);
Long-Term Memory (LRM − 18.3, p < 0.0001); Processing
Speed (LRM − 17.2, p < 0.0001; Phonemic Awareness
(LRM − 8.5, p = 0.004); Working Memory (LRM − 11.2,
p = 0.001); Cognitive Fluency (LRM − 14.8, p < 0.0001); and
Executive Processes (LRM − 17.1, p < 0.0001).
Batería-III subtests An exploratory examination of
group differences on the Batería-III subtests was conducted
to determine if any of the subtests were influential in the
summary score findings. Specifically, 13 of the 15 subtests
produced significant group differences, with FAP cases per-
forming below controls on each of these 13 subtests. Effect
sizes were in the large range in every instance. After Bon-
feronni Correction (i.e., p < 0.003), nine of the Batería-III
subtests remained statistically significant including: Verbal
Comprehension, Visual-Auditory Learning, Spatial Rela-
tions, Sound Blending, Concept Formation, Visual Match-
ing, Auditory Working Memory, Retrieval Fluency, and
Decision Speed.
Group differences in ratings of executive functions
We only had five cases where parents and child needed
to complete the BRIEF, and all fell within the average
range. Consequently, given the small sample size, no fur-
ther analysis was conducted (data not shown). For the
Adult BRIEF, both cases and controls rated their execu-
tive functioning to be within the average range. Group
comparisons (FAP cases vs. controls) did not show any
significant differences on any of the individual or sum-
mary scales of the BRIEF-Adult (Table 2).
Genotype-phenotype correlation analysis
Neurocognitive status was analyzed according to APC
mutation location (Table 3). FAP cases were grouped in
two categories based on APC gene mutations: attenuated
FAP (mutations in codons < 1000 and > 1500; N = 9) and
classic FAP, those with an APC gene mutation in the
mutation cluster region (between codons 1000 to 1500;
Table 1 Baseline demographic characteristics of study participants
Characteristic FAP group (n = 26) Control group (n = 25) p-value*
Age 0.59
< 21 years 8 (30.8) 6 (24.0)
≥ 21 years 18 (69.2) 19 (76.0)
Mean ± SD 34.2 ± 15.0 32.7 ± 13.8
Gender 0.68
Male 14 (53.9) 12 (48.0)
Female 12 (46.2) 13 (52.0)
Medical insurance 0.28
None 1 (4.2) 2 (8.3)
Private 13 (54.1) 17 (70.8)
Public 10 (41.7) 5 (20.8)
Educational level 0.09
< 12 4 (15.4) 9 (36.0)
≥ 12 22 (84.6) 16 (64.0)
Grade repetitions 0.45
No 15 (57.7) 17 (68.0)
Yes 11 (42.3) 8 (32.0)
*p-value from the χ2 test or Fisher’s exact test
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N = 17). The two groups did not differ on age or gender
(p > 0.05), respectively (data not shown). Findings re-
vealed that the two FAP groups were not significantly
different on IQ (p = 0.709). However, FAP cases with
mutations located within the classic mutation cluster
had marginally lower performance on Woodcock-
Muñoz summary scores of Cognitive Efficiency (p =
0.076) and Processing Speed, (p = 0.056), and on BRIEF-
Adult scales of Shift (p = 0.058) and Initiate (p = 0.081)
compared to FAP cases with mutations in the attenuated
FAP region (Table 3).
Neurological examination
A full neurologic examination was performed in all 26
cases and in 24 controls. No consistent pattern of abnor-
malities was observed in the cases or control subjects.
Four cases showed findings consistent with a mild distal
sensory neuropathy, in three of the cases this was related
to prior chemotherapy for colon cancer.
Discussion
The findings of this study provide a proof-of-concept for
an important role of the APC protein in neurocognitive
function. Moreover, this investigation is the first to sys-
tematically evaluate neurocognition in the FAP popula-
tion using a carefully matched case-control design, and
evaluating important potential confounders such as anx-
iety, depression, and level of education. Our findings
reflected significantly lower performance on IQ and in a
variety of neurocognitive functions, with effect sizes be-
ing within the large range. Furthermore, for many of the
specific neurocognitive functions, individuals with
FAP performed in the bottom quartile, suggesting
possible difficulties in these areas. Interestingly, there
were no group differences noted on the adult self-
ratings (BRIEF questionnaire) of executive functions,
perhaps secondary to self-perceptions not recognizing
the subtle differences that might be present when
compared to their peers.
Table 2 Comparison of the FAP and control groups on the neurocognitive functions
Measure FAP group
(n = 26)
Control group (n =
25)
p-value* Simple LRM
(coefficients)
p-value Adjusted
multivariate
LRM**
(coefficients)
p-value Adjusted
multivariate
LRM***
(coefficients)
p-value
Mean SD Mean SD
TONI-4 IQ 90.5 5.6 95.6 6.8 0.005 −5.1 0.005 −5.2 0.005 −5.0 0.008
Batería III clusters
Verbal ability# 88.2 7.7 95.7 7.8 0.001 −7.5 0.001 −7.4 0.001 −7.2 0.002
Thinking ability# 80.5 10.5 97.8 10.3 < 0.0001 −17.3 < 0.0001 −16.7 < 0.0001 − 16.9 < 0.0001
Cognitive efficiency# 81.1 11.9 94.7 9.9 0.0001 −13.6 < 0.0001 − 13.4 < 0.0001 − 13.3 < 0.0001
Long-term memory# 66.8 14.3 85.1 12.1 < 0.0001 −18.3 < 0.0001 −17.8 < 0.0001 − 18.3 < 0.0001
Processing speed# 85.1 14.7 102.0 9.7 < 0.0001 −16.9 < 0.0001 − 16.6 < 0.0001 − 17.2 < 0.0001
Phonemic awareness 88.6 10.8 97.6 8.7 0.002 −8.9 0.002 −8.7 0.002 −8.5 0.004
Working memory# 84.4 10.7 95.6 11.4 0.0007 − 11.1 0.001 − 11.2 0.001 −11.2 0.001
Cognitive fluency# 78.3 12.2 91.8 9.9 0.0001 −13.5 < 0.0001 − 13.5 < 0.0001 − 14.8 < 0.0001
Executive processes# 83.8 13.7 100.8 9.7 < 0.0001 −17.0 < 0.0001 − 17.0 < 0.0001 − 17.1 < 0.0001
BRIEF-Adult
Inhibit 49.3 7.9 47.1 7.0 0.319 2.3 0.319 2.4 0.305 2.0 0.385
Shift 51.8 10.3 48.9 11.9 0.256 2.9 0.391 3.2 0.391 2.9 0.396
Emotional control 51.5 8.6 47.7 10.2 0.067 3.9 0.180 4.0 0.162 3.6 0.225
Self-monitor 49.5 8.6 46.4 9.8 0.212 3.1 0.270 3.2 0.251 3.1 0.291
Initiate 50.5 10.9 49.2 9.4 0.795 1.3 0.677 1.5 0.626 1.5 0.642
Working memory 53.7 11.5 49.4 8.9 0.218 4.3 0.178 4.6 0.112 4.4 0.180
Plan/Organize 50.3 10.9 49.0 13.9 0.587 1.3 0.731 1.7 0.622 1.1 0.772
Task monitor 51.5 11.5 48.7 8.7 0.571 2.8 0.372 3.2 0.240 2.4 0.452
Organization of materials 49.8 8.2 50.3 8.7 0.870 −0.4 0.870 −0.2 0.929 −0.7 0.779
Behavior regulation index 50.8 8.8 47.6 10.5 0.266 3.3 0.266 3.5 0.214 3.3 0.278
Metacognitive index 51.1 10.8 49.2 9.8 0.595 1.9 0.549 2.2 0.441 1.7 0.589
Global executive composite 51.1 10.0 48.3 10.1 0.272 2.8 0.356 3.1 0.264 2.7 0.389
*p-values from the T-test or Wilcoxon rank-sum (Mann-Whitney) test; **Adjusted by age and gender; ***Adjusted by education. LRM Linear Regression Models.
#Neurocognitive measures are significant under the Bonferroni-Holmes corrections for all the statistical tests simultaneously
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Original observations describing intellectual disabilities
among individuals with FAP were limited to case reports
[4, 5, 7]. Patients with FAP were shown to perform lower
on test of intellectual capacity, particularly on verbal
tasks, when compared to patients with ulcerative colitis
[14]. In addition, a conference presentation by O’Malley
et al. [13] directly examined the cognitive functioning of
individuals with FAP by conducting a brief intelligence
test with 44 adult subjects from 42 families. They found
that the group performed in the average IQ range, with
27% of the sample performing in the bottom quartile.
Verbal abilities were significantly lower than average, al-
though not impaired (Verbal IQ = 95.5 ± 12), with the
majority of participants having their verbal abilities sig-
nificantly lower than their nonverbal abilities (p = 0.020).
Our nonverval abilities were similar in the level to that
obtained by O’Malley et al. The authors hypothesize that
the APC protein was critical for dependent pathways in
the cochlea and could have a role in (verbal) cognition.
In contrast, our investigation is the first to incorporate
an age-, gender-, and education-matched control group
with a complete battery of neurocognitive tests enabling
interrogation of multiple domains and corresponding
anatomical regions. Moreover, our scientific rationale
differs from that of previous investigators as it relates to
the central role of the APC protein in the development of
the synaptic complex in the central nervous system [2,
3].
The APC protein has multiple domains and binding
patterns, which indicates a multi-functional nature [15].
The classic colorectal adenomatous polyposis seen in pa-
tients with FAP results from the known negative regula-
tion of APC protein in the Wnt transcription pathway
[16]. The APC protein also carries out microtubule-
Table 3 Comparisons of FAP Severity Groups on Neurocognitive Functions
Measure Attenuated
FAP Group
(n = 9)
Classic FAP
Group
(n = 17)
p-value* Simple LRM
(coefficients)
p-value Adjusted multivariate
LRM** (coefficients)
p-value Adjusted multivariate
LRM*** (coefficients)
p-value
Mean SD Mean SD
TONI-4 IQ 91.2 4.5 90.2 6.3 0.662 −1.0 0.662 −1.0 0.670 −0.9 0.709
Batería III clusters
Verbal ability 89.7 5.5 87.4 8.7 0.479 −2.3 0.479 −2.3 0.504 −2.0 0.566
Thinking ability 81.8 10.0 79.9 10.9 0.669 −1.9 0.669 −2.0 0.671 −1.8 0.704
Cognitive efficiency 87.2 6.4 77.8 13.0 0.054 −9.4 0.054 −9.4 0.064 −9.2 0.076
Long-term memory 65.0 16.2 67.7 13.6 0.655 2.7 0.655 2.4 0.677 2.6 0.666
Processing speed 92.9 7.9 81.0 16.0 0.048 −11.9 0.048 −12.1 0.045 −11.4 0.056
Phonemic awareness 91.1 11.1 87.3 10.7 0.400 −3.8 0.400 −3.8 0.419 −4.2 0.379
Working memory 88.6 6.6 82.2 11.9 0.154 −6.3 0.154 −6.2 0.168 −6.1 0.189
Cognitive fluency 82.4 11.0 76.1 12.5 0.210 −6.4 0.210 −6.5 0.164 −6.2 0.193
Executive processes 84.8 10.8 83.2 15.3 0.791 −1.5 0.791 −1.6 0.781 −1.0 0.862
BRIEF-Adult
Inhibit 50.4 5.9 48.8 8.8 0.657 −1.6 0.657 −1.3 0.712 −0.5 0.886
Shift 57.1 8.1 49.1 10.4 0.052 −8.1 0.068 −7.6 0.055 −7.9 0.058
Emotional control 52.5 6.1 51.0 9.8 0.519 −1.5 0.696 −1.2 0.742 −1.3 0.726
Self-monitor 52.4 9.3 48.9 8.1 0.229 −4.4 0.249 −4.0 0.253 −5.2 0.134
Initiate 55.8 12.2 47.9 9.5 0.070 −7.9 0.095 −7.4 0.082 −7.9 0.081
Working memory 52.9 12.6 54.1 11.4 0.735 1.2 0.818 1.8 0.663 1.3 0.760
Plan/Organize 54.3 12.3 48.3 9.9 0.176 −5.9 0.214 −5.3 0.158 −5.5 0.162
Task monitor 54.8 10.9 49.9 11.8 0.310 −4.8 0.345 −4.1 0.287 −3.6 0.369
Organization of
materials
50.8 8.6 49.4 8.2 0.706 −1.4 0.706 −1.1 0.744 −0.5 0.882
Behavior regulation
index
53.6 6.7 49.4 9.6 0.281 −4.2 0.281 −3.7 0.270 −3.8 0.283
Metacognitive index 53.9 11.5 49.7 10.5 0.443 −4.2 0.380 −3.6 0.344 −3.6 0.361
Global executive
composite
54.1 9.2 49.6 10.2 0.297 −4.6 0.300 −4.0 0.253 −4.0 0.276
*p-values from T-test or Wilcoxon rank-sum (Mann-Whitney) test; **Adjusted by age and gender; ***Adjusted by age, gender and education
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organizing functions in neurons [17–19], and has a role
in synapse assembly [20]. The APC protein is found in
many cell types including neurons in the adult rodent
brain [21], and high levels of expression of the APC
mRNA are observed during brain development [22, 23].
Moreover, APC protein functions in localizing nicotinic
acetylcholine receptors (nAChRs) at neuronal synapses
in vivo [24] organizing a multi-molecular complex that
stabilizes the local cytoskeleton and links the alpha-
3nAChRs subunit to APC at postsynaptic sites [2]. This
complex of proteins is required for coordinating pre-
synaptic and postsynaptic maturation in cholinoceptive
neurons in vertebrate animals [24]. This complex is vital
in processing information as nicotinic receptors have a
key role in attention, learning, and memory and are
highly concentrated in the cerebral cortex, hippocampus,
thalamus and limbic system [25]. Thus, truncated or ab-
sence of the APC protein in the brain among patients
with FAP may result in altered neurocognitive functions
including attention deficits and learning impairments,
and our findings provide preliminary support for these
assertions. Given the pathophysiology inherent in these
processes, we had hypothesized that patients with FAP
would show lower processing speed and cognitive effi-
ciency than controls and, in fact, this is what was uncov-
ered. This was in addition to a significant lower
performance than controls in a host of other neurocog-
nitive domains.
In an elegant study using a conditional APC knockout
mouse with deletion targeted predominantly to forebrain
excitatory neurons (hippocampus and cortex), Mohn
et al. reported impaired hippocampal-dependent spatial
learning [8]. APC knock-out mice had double the la-
tency to goal, committing three times as many errors,
and took less efficient routes to the goal compared to
wild-type mice [8]. In this in vivo model, APC loss lead
to excessive B-catenin and Wnt signal transduction in
the forebrain as well as cognitive impairments and an
autistic-like presentation [8]. Similarly, Koshimizu et al.
had reported that the APC gene plays a role in locomo-
tion and working memory performance. These investiga-
tors reported decreased locomotor activity and age-
dependent working memory deficits using a heterozy-
gous APC knockout mice model [26]. Hence, our clinical
observations of significantly lower performance on IQ
and a variety of specific neurocognitive functions among
patients with FAP as compared to controls may result
from defective APC protein in the synaptic complex in
the central nervous system.
Most mutations found in patients with FAP represent
truncating mutations of the APC gene [1] and clinical
presentations typically follow a genotype-phenotype pat-
tern although there are known exceptions [27, 28]. For
instance, severe colorectal polyposis (> 1000 adenomas)
correlates with mutations between codons 1250 and
1464 [29], while desmoid tumors may be more prevalent
in persons with mutations after codon 1444 [30, 31]. In
our current study, we examined neurocognitive func-
tions across two genetically defined subgroups including
individuals with attenuated-FAP and those with classic
FAP as defined by the location of their APC mutations.
The location of the mutation in the APC gene correlates
with the length and function of the APC protein, with
less function seen among those with mutations in the
classic FAP region. Our exploratory analysis suggests dif-
ferences in several categories including cognitive effi-
ciency and processing speed, and selected executive
functions (set shifting, initiation) with higher perform-
ance among patients with attenuated-FAP compared to
those with classic FAP.
Evidence for a potential etiologic role of APC protein
in neurodevelopmental disorders arises from human
studies examining the association of APC gene polymor-
phisms and autism spectrum disorders [32]. Neurodeve-
lopmental disorders such as autism spectrum disorder,
bipolar disorder and schizophrenia may result from dys-
regulation of Wnt signaling [33], which is also seen in
patients with FAP. Furthermore, deletions of the APC
gene and occurrence of adenomatous polyposis have
been reported in patients originally referred for autism
[34]. In our Polyposis Registry [1], we have several pa-
tients with either mutations and/or deletion of the APC
gene who are also diagnosed with autism spectrum dis-
order. The APC gene has also been claimed to be associ-
ated with susceptibility to schizophrenia [10], providing
an additional line of evidence for the important role that
APC protein may have in the etiology of neurodevelop-
mental disorders. Our study provides proof-of-concept
and preliminary clinical data of the ubiquitous deficit in
neurocognitive functions associated with mutations in
the APC gene in a genetically defined syndrome.
The pervasive nature of the observed cognitive dys-
function suggests that loss or dysfunction of the APC
protein occurs across the cerebral cortex. Moreover, the
observed neurocognitive dysfunction followed a
genotype-phenotype correlation as occurs with other
clinical manifestations in FAP patients. However, as FAP
is a chronic debilitating disease that impacts individuals
from early adolescence it may negatively affect cognition
by altering educational milestones due to medical/surgi-
cal management of the condition. We thus reviewed and
contrasted the effect on neurocognitive outcomes in two
well characterized genetically-driven chronic illnesses,
Cystic Fibrosis and Sickle Cell Anemia [35–37]. Results
of these studies showed that children with Cystic Fibro-
sis had general intelligence levels that were comparable
to the general population of the same age group [36].
Furthermore, a study on psychological assessment in
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adults with Cystic Fibrosis could not detect an increase
in depressive or anxiety related symptoms in the affected
adults [38]. In contrast, studies on the neurocognitive ef-
fects in children and adolescents with Sickle Cell
Anemia reported learning difficulties [37], need for spe-
cial education supports [37], lower visual-motor abilities
[39], and decreased verbal short-term memory [35].
These neurocognitive effects were associated with the
severity of the Sickle Cell Anemia, which suggest the
mechanism for the neurocognitive deficits observed is
reduced oxygen delivery rather than other confounding
social determinants [35, 37]. The mechanism by which
APC mutations cause neurocognitive dysfunction results
from the major role of the APC protein in the develop-
ment of the pre-post synaptic complex [2, 3]. Thus, the
mechanisms by which the neurocognitive deficits
present in both illnesses (FAP vs. Sickle Cell Anemia)
differ in etiology. Our study serves as a proof-of-concept
for the potential role of APC protein in neurocognition
among patients with FAP; however, our study could not
fully account for the possible confounding effect on cog-
nition of having a chronic condition, such as school ab-
senteeism, frequent medical visits, among others.
It is also important to explore how patients with FAP
might react to the results obtained in this pilot study, by
examining the attitudes, emotional impact and percep-
tions of these individuals regarding their cognitive abil-
ities. While we are clearly cognizant of this being yet
another potential worry for patients with FAP and their
families, early recognition of potential risk for cognitive
difficulties might lay the foundation for earlier interven-
tion and, perhaps, lessening or preventing such difficulties
over the life course for individuals with FAP. Studies on
the effects of other chronic illnesses affecting children and
young adults are needed to fully elucidate if the neurocog-
nitive effects seen in patients with FAP are partly due to a
defective/truncated APC protein and not by other con-
founders. Our proof-of-concept findings would suggest
that this is a viable path for further scientific inquiry.
Conclusion
Our study in a genetically defined hereditary syndrome
provides preliminary clinical data supporting an important
role of the APC protein in neurocognitive function and of
the pervasive neurocognitive dysfunctions that may be as-
sociated with mutations in the APC gene. Validation of
our current observations in larger ethnically diverse co-
horts would support cognitive screening for individuals
with FAP to establish therapeutic interventions early in life
as done for other neurodevelopmental disorders. Hence,
studies examining the role of the APC protein among in-
dividuals with other neurodevelopmental conditions that
manifest cognitive impairment, such as autism spectrum
disorders and schizophrenia [40, 41] are warranted.
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